WeTrials is proud to announce a new strategic partnership with GenomOncology, a leading precision medicine software company. Together, we are working to help central nervous system (CNS) cancer patients access and enroll in clinical trials faster.

This collaboration also expands on the existing partnership between GenomOncology and Belay Diagnostics, creating a more complete and seamless pathway from molecular diagnosis directly to trial enrollment.

Connecting Molecular Diagnosis to Trial Enrollment

Earlier this year, Belay Diagnostics integrated GenomOncology’s GO Pathology Workbench into the variant interpretation workflow for its Summit™ 2.0 liquid biopsy test—a cerebrospinal fluid (CSF) assay that informs the diagnosis and management of primary and secondary CNS malignancies.

Building on that foundation, the GO Genomic Report generated through this workflow will now include a direct link to the WeTrials platform.

With a single click, clinicians can move from a patient’s molecular report—which includes GenomOncology’s matched clinical trial recommendations—directly into our patient-friendly trial information page. Once on the WeTrials platform, complex studies are simplified, and patients can easily explore their enrollment options.

Putting Patients First: Perspectives from Leadership

Alireza Mansouri, MD, Co-Founder and Chief Medical Officer of WeTrials:
“We built WeTrials on the belief that clinical trials should never be the last resort, but a first consideration. When a clinician, or even a patient, can go directly from a genomic report to our platform, then pursue trial enrollment in a streamlined process, the barriers to enrollment drop significantly. Together with GenomOncology and Belay Diagnostics, we can ensure that molecular insights open the door to innovative therapies patients might otherwise never have known existed.”

Garreth Hippe, Chief Commercial Officer at GenomOncology:
“The trial matches we surface in our genomic reports need to lead to action. By embedding a direct link to WeTrials within the GO Genomic Report, we’re giving clinicians an immediate on-ramp to enrollment support without adding complexity to their workflow. We’re proud to expand on the outstanding work with Belay Diagnostics to build something that truly puts patients first, and not just for Belay but for all of our customers.”

Dr. Honey Reddi, PhD, FACMG, Chief Laboratory Officer at Belay Diagnostics:
“Our goal has always been to make sure the molecular information uncovered through the Summit™ test translates into real options for patients. This collaboration with WeTrials puts the right resources directly in the hands of clinicians at the point of reporting, so, when advised, patients can move from diagnosis to clinical trial enrollment faster than ever before.”

Looking Ahead

The initial phase of our partnership will focus specifically on CNS cancer patients tested through Belay Diagnostics. However, this integration will ultimately be made available to all GenomOncology customers. Over time, we plan to expand this streamlined enrollment pathway to additional diagnostic partners and various other cancer types.

Read the full press release: https://www.prnewswire.com/news-releases/genomoncology-announces-strategic-partnership-with-wetrials-to-accelerate-clinical-trial-enrollment-for-cns-cancer-patients-302709691.html?tc=eml_cleartime